SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (NASDAQ:SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that the company’s shares have been added to the broad-market Russell 3000® Index, the Russell 2000® Index, Russell Global Index and Russell Microcap® Index following Russell Investments’ reconstitution of its comprehensive set of U.S. and global equity indexes after market close on June 25, according to an updated list of additions posted June 25 on www.russell.com.
